TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Pioglitazone in Alzheimer Disease Progression
Brief Summary: This study was designed to assess the safety and tolerability of pioglitazone, an approved drug for type 2 diabetes, in non diabetic patients with Alzheimer's disease. It was also designed to generate preliminary information on whether pioglitazone might slow progression of Alzheimer's disease.


Options:
A: Arm Label: PGZ; Type: EXPERIMENTAL; Interventions: Drug: pioglitazone | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: pioglitazone; Assigned to Arm(s): PGZ | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Vitamin E; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Vitamin E | Arm Label: Vitamin C; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Vitamin C | Arm Label: Multivitamin; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Multivitamin | Arm Label: Beta-carotene; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Beta-carotene | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin E; Assigned to Arm(s): Vitamin E | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin C; Assigned to Arm(s): Vitamin C | Intervention Type: DIETARY_SUPPLEMENT; Name: Multivitamin; Assigned to Arm(s): Multivitamin | Intervention Type: DIETARY_SUPPLEMENT; Name: Beta-carotene; Assigned to Arm(s): Beta-carotene
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Vitamin E, Vitamin C, and Alpha-lipoic Acid, Drug: Placebo wafers | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Coenzyme Q, Drug: Placebo capsules | Arm Label: 3; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo capsules, Drug: Placebo wafers | Intervention Type: DRUG; Name: Vitamin E, Vitamin C, and Alpha-lipoic Acid; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Coenzyme Q; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Placebo capsules; Assigned to Arm(s): 2, 3 | Intervention Type: DRUG; Name: Placebo wafers; Assigned to Arm(s): 1, 3
D: Arm Label: Vitamin E + selenium placebo; Type: EXPERIMENTAL; Interventions: Drug: Vitamin E, Other: selenium placebo | Arm Label: Selenium + vitamin E placebo; Type: EXPERIMENTAL; Interventions: Drug: Selenium, Other: Vitamin E placebo | Arm Label: Vitamin E + selenium; Type: EXPERIMENTAL; Interventions: Drug: Vitamin E, Drug: Selenium | Arm Label: Vitamin E placebo + selenium placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Vitamin E placebo, Other: selenium placebo | Intervention Type: DRUG; Name: Vitamin E; Assigned to Arm(s): Vitamin E + selenium, Vitamin E + selenium placebo | Intervention Type: DRUG; Name: Selenium; Assigned to Arm(s): Selenium + vitamin E placebo, Vitamin E + selenium | Intervention Type: OTHER; Name: Vitamin E placebo; Assigned to Arm(s): Selenium + vitamin E placebo, Vitamin E placebo + selenium placebo | Intervention Type: OTHER; Name: selenium placebo; Assigned to Arm(s): Vitamin E + selenium placebo, Vitamin E placebo + selenium placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Pioglitazone in Alzheimer Disease Progression
Brief Summary: This study was designed to assess the safety and tolerability of pioglitazone, an approved drug for type 2 diabetes, in non diabetic patients with Alzheimer's disease. It was also designed to generate preliminary information on whether pioglitazone might slow progression of Alzheimer's disease.


Options:
A: Arm Label: MRI(+ve),; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: 200mg of Palm vitamin E (tocotrienols) or placebo | Arm Label: MRI(-ve); Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: 200mg of Palm vitamin E (tocotrienols) or placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: 200mg of Palm vitamin E (tocotrienols) or placebo; Assigned to Arm(s): MRI(+ve),, MRI(-ve)
B: Arm Label: Nutriceutical formulation; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Nutriceutical formulation | Arm Label: Placebo 1; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: Placebo 2; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Nutriceutical formulation; Assigned to Arm(s): Nutriceutical formulation | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo 1, Placebo 2
C: Arm Label: PGZ; Type: EXPERIMENTAL; Interventions: Drug: pioglitazone | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: pioglitazone; Assigned to Arm(s): PGZ | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: 1; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Study Arm A | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Study Arm B | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Study Arm C | Arm Label: 4; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Study Arm D | Intervention Type: DIETARY_SUPPLEMENT; Name: Study Arm A; Assigned to Arm(s): 1 | Intervention Type: DIETARY_SUPPLEMENT; Name: Study Arm B; Assigned to Arm(s): 2 | Intervention Type: DIETARY_SUPPLEMENT; Name: Study Arm C; Assigned to Arm(s): 3 | Intervention Type: DIETARY_SUPPLEMENT; Name: Study Arm D; Assigned to Arm(s): 4

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Pioglitazone in Alzheimer Disease Progression
Brief Summary: This study was designed to assess the safety and tolerability of pioglitazone, an approved drug for type 2 diabetes, in non diabetic patients with Alzheimer's disease. It was also designed to generate preliminary information on whether pioglitazone might slow progression of Alzheimer's disease.


Options:
A: Arm Label: 1; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Study Arm A | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Study Arm B | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Study Arm C | Arm Label: 4; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Study Arm D | Intervention Type: DIETARY_SUPPLEMENT; Name: Study Arm A; Assigned to Arm(s): 1 | Intervention Type: DIETARY_SUPPLEMENT; Name: Study Arm B; Assigned to Arm(s): 2 | Intervention Type: DIETARY_SUPPLEMENT; Name: Study Arm C; Assigned to Arm(s): 3 | Intervention Type: DIETARY_SUPPLEMENT; Name: Study Arm D; Assigned to Arm(s): 4
B: Intervention Type: BEHAVIORAL; Name: ascorbic acid, vitamin E, beta carotene, selenium, zinc; Assigned to Arm(s): N/A
C: Arm Label: Vitamin E + selenium placebo; Type: EXPERIMENTAL; Interventions: Drug: Vitamin E, Other: selenium placebo | Arm Label: Selenium + vitamin E placebo; Type: EXPERIMENTAL; Interventions: Drug: Selenium, Other: Vitamin E placebo | Arm Label: Vitamin E + selenium; Type: EXPERIMENTAL; Interventions: Drug: Vitamin E, Drug: Selenium | Arm Label: Vitamin E placebo + selenium placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Vitamin E placebo, Other: selenium placebo | Intervention Type: DRUG; Name: Vitamin E; Assigned to Arm(s): Vitamin E + selenium, Vitamin E + selenium placebo | Intervention Type: DRUG; Name: Selenium; Assigned to Arm(s): Selenium + vitamin E placebo, Vitamin E + selenium | Intervention Type: OTHER; Name: Vitamin E placebo; Assigned to Arm(s): Selenium + vitamin E placebo, Vitamin E placebo + selenium placebo | Intervention Type: OTHER; Name: selenium placebo; Assigned to Arm(s): Vitamin E + selenium placebo, Vitamin E placebo + selenium placebo
D: Arm Label: PGZ; Type: EXPERIMENTAL; Interventions: Drug: pioglitazone | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: pioglitazone; Assigned to Arm(s): PGZ | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: NN1250-3583: A 52 Week Randomised, Controlled, Open Label, Multicentre, Multinational, Parallel, Treat-to-target Trial Comparing Efficacy and Safety of SIBA and Insulin Glargine Both Administered Once Daily in a Basal-bolus Regimen With Insulin Aspart as Mealtime Insulin in Subjects With Type 1 Diabetes (BEGIN™: BB T1 LONG) / NN1250-3644: An Extension Trial to Trial NN1250-3583 Comparing Safety and Efficacy of NN1250 With Insulin Glargine, Both With Insulin Aspart as Meal-time Insulin, in Type 1 Diabetes (BEGIN™: T1)
Brief Summary: This trial is conducted in Africa, Europe and the United States of America (USA).

The aim of the trial is to compare NN1250 (insulin degludec, soluble insulin basal analogue (SIBA)) plus insulin aspart with insulin glargine (IGlar) plus insulin aspart in patients with type 1 diabetes.

The main period is registered internally at Novo Nordisk as NN1250-3583 while the extension period is registered as NN1250-3644.


Options:
A: Arm Label: IDeg OD ± OADs followed by IGlar OD ± OADs; Type: EXPERIMENTAL; Interventions: Drug: insulin degludec, Drug: insulin glargine | Arm Label: IGlar OD ± OADs followed by IDeg OD ± OADs; Type: ACTIVE_COMPARATOR; Interventions: Drug: insulin degludec, Drug: insulin glargine | Intervention Type: DRUG; Name: insulin degludec; Assigned to Arm(s): IDeg OD ± OADs followed by IGlar OD ± OADs, IGlar OD ± OADs followed by IDeg OD ± OADs | Intervention Type: DRUG; Name: insulin glargine; Assigned to Arm(s): IDeg OD ± OADs followed by IGlar OD ± OADs, IGlar OD ± OADs followed by IDeg OD ± OADs
B: Arm Label: Insulin Degludec + Insulin Aspart; Type: EXPERIMENTAL; Interventions: Drug: insulin degludec, Drug: insulin aspart | Arm Label: Insulin Detemir +Insulin Aspart; Type: EXPERIMENTAL; Interventions: Drug: insulin detemir, Drug: insulin aspart | Intervention Type: DRUG; Name: insulin degludec; Assigned to Arm(s): Insulin Degludec + Insulin Aspart | Intervention Type: DRUG; Name: insulin detemir; Assigned to Arm(s): Insulin Detemir +Insulin Aspart | Intervention Type: DRUG; Name: insulin aspart; Assigned to Arm(s): Insulin Degludec + Insulin Aspart, Insulin Detemir +Insulin Aspart
C: N/A
D: Arm Label: IDeg OD; Type: EXPERIMENTAL; Interventions: Drug: insulin degludec, Drug: insulin aspart | Arm Label: IGlar OD; Type: ACTIVE_COMPARATOR; Interventions: Drug: insulin glargine, Drug: insulin aspart | Intervention Type: DRUG; Name: insulin degludec; Assigned to Arm(s): IDeg OD | Intervention Type: DRUG; Name: insulin glargine; Assigned to Arm(s): IGlar OD | Intervention Type: DRUG; Name: insulin aspart; Assigned to Arm(s): IDeg OD, IGlar OD

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Vitamin D Supplementation After Successful Parathyroid Surgery for Primary Hyperparathyroidism
Brief Summary: A randomised double blind clinical trial, accepted by the Medical Products Agency and registered in the European Clinical Trials Database. Aims to evaluate the prevalence of vitamin D deficiency in a pHPT population in relation to gender and age, the correlation between vitamin D status, pre- and postoperative parathyroid hormone level and bone density and the correlation between vitamin D status, metabolic, cardiovascular risk factors and QoL aspects before and after parathyroid adenomectomy.


Options:
A: Arm Label: cholecalciferol and calcium carbonate; Type: EXPERIMENTAL; Interventions: Drug: calcium carbonate | Arm Label: calciumcarbonate; Type: ACTIVE_COMPARATOR; Interventions: Drug: cholecalciferol and calcium carbonate | Intervention Type: DRUG; Name: cholecalciferol and calcium carbonate; Assigned to Arm(s): calciumcarbonate | Intervention Type: DRUG; Name: calcium carbonate; Assigned to Arm(s): cholecalciferol and calcium carbonate
B: Arm Label: Early parathyroidectomy group; Type: EXPERIMENTAL; Interventions: Procedure: Early parathyroidectomy group (EPTX-group) | Arm Label: Late parathyroidectomy group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: Early parathyroidectomy group (EPTX-group); Assigned to Arm(s): Early parathyroidectomy group
C: Arm Label: Parathyroidectomy + Observation; Type: EXPERIMENTAL; Interventions: Procedure: Parathyroid Surgery, Behavioral: Telephone Interview, Behavioral: Polysomnography (PSG) | Arm Label: Observation Alone; Type: OTHER; Interventions: Behavioral: Telephone Interview, Procedure: Parathyroid Surgery, Behavioral: Polysomnography (PSG) | Intervention Type: PROCEDURE; Name: Parathyroid Surgery; Assigned to Arm(s): Parathyroidectomy + Observation | Intervention Type: BEHAVIORAL; Name: Telephone Interview; Assigned to Arm(s): Observation Alone, Parathyroidectomy + Observation | Intervention Type: PROCEDURE; Name: Parathyroid Surgery; Assigned to Arm(s): Observation Alone | Intervention Type: BEHAVIORAL; Name: Polysomnography (PSG); Assigned to Arm(s): Observation Alone, Parathyroidectomy + Observation
D: N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase II, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, and Tolerability of Intravenous huMAb OX40L (RO4989991) in the Prevention of Allergen-Induced Airway Obstruction in Adults With Mild Allergic Asthma
Brief Summary: This Phase II, double-blind, placebo-controlled, randomized, parallel-group study is designed to evaluate the efficacy, safety, and tolerability of huMAb OX40L administered to patients by IV infusion for the treatment of allergen-induced asthma.


Options:
A: Arm Label: Benralizumab 30 mg q.4 weeks; Type: EXPERIMENTAL; Interventions: Biological: Benralizumab | Arm Label: Benralizumab 30 mg q.8 weeks; Type: EXPERIMENTAL; Interventions: Biological: Benralizumab | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Intervention Type: BIOLOGICAL; Name: Benralizumab; Assigned to Arm(s): Benralizumab 30 mg q.4 weeks, Benralizumab 30 mg q.8 weeks | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: MEDI528 30 mg; Type: EXPERIMENTAL; Interventions: Biological: MEDI528 30 mg | Arm Label: MEDI528 100 mg; Type: EXPERIMENTAL; Interventions: Biological: MEDI528 100 mg | Arm Label: MEDI528 300 mg; Type: EXPERIMENTAL; Interventions: Biological: MEDI528 300 mg | Arm Label: Placebo; Type: EXPERIMENTAL; Interventions: Other: Placebo | Intervention Type: BIOLOGICAL; Name: MEDI528 30 mg; Assigned to Arm(s): MEDI528 30 mg | Intervention Type: BIOLOGICAL; Name: MEDI528 100 mg; Assigned to Arm(s): MEDI528 100 mg | Intervention Type: BIOLOGICAL; Name: MEDI528 300 mg; Assigned to Arm(s): MEDI528 300 mg | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: CAT-354 1 mg/kg; Type: EXPERIMENTAL; Interventions: Biological: CAT-354 1mg/kg | Arm Label: CAT-354 5 mg/kg; Type: EXPERIMENTAL; Interventions: Biological: CAT-354 5 mg/kg | Arm Label: CAT-354 10mg/kg; Type: EXPERIMENTAL; Interventions: Biological: CAT-354 10mg/kg | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: BIOLOGICAL; Name: CAT-354 1mg/kg; Assigned to Arm(s): CAT-354 1 mg/kg | Intervention Type: BIOLOGICAL; Name: CAT-354 5 mg/kg; Assigned to Arm(s): CAT-354 5 mg/kg | Intervention Type: BIOLOGICAL; Name: CAT-354 10mg/kg; Assigned to Arm(s): CAT-354 10mg/kg | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: huMAb OX40L; Type: EXPERIMENTAL; Interventions: Drug: huMAb OX40L | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: huMAb OX40L; Assigned to Arm(s): huMAb OX40L | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase II, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, and Tolerability of Intravenous huMAb OX40L (RO4989991) in the Prevention of Allergen-Induced Airway Obstruction in Adults With Mild Allergic Asthma
Brief Summary: This Phase II, double-blind, placebo-controlled, randomized, parallel-group study is designed to evaluate the efficacy, safety, and tolerability of huMAb OX40L administered to patients by IV infusion for the treatment of allergen-induced asthma.


Options:
A: Intervention Type: DRUG; Name: SB-240563 (Mepolizumab); Assigned to Arm(s): N/A
B: Arm Label: huMAb OX40L; Type: EXPERIMENTAL; Interventions: Drug: huMAb OX40L | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: huMAb OX40L; Assigned to Arm(s): huMAb OX40L | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo
C: Arm Label: CAT-354 1 mg/kg; Type: EXPERIMENTAL; Interventions: Biological: CAT-354 1mg/kg | Arm Label: CAT-354 5 mg/kg; Type: EXPERIMENTAL; Interventions: Biological: CAT-354 5 mg/kg | Arm Label: CAT-354 10mg/kg; Type: EXPERIMENTAL; Interventions: Biological: CAT-354 10mg/kg | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: BIOLOGICAL; Name: CAT-354 1mg/kg; Assigned to Arm(s): CAT-354 1 mg/kg | Intervention Type: BIOLOGICAL; Name: CAT-354 5 mg/kg; Assigned to Arm(s): CAT-354 5 mg/kg | Intervention Type: BIOLOGICAL; Name: CAT-354 10mg/kg; Assigned to Arm(s): CAT-354 10mg/kg | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Reslizumab - 0.3 mg/kg; Type: EXPERIMENTAL; Interventions: Drug: Reslizumab | Arm Label: Reslizumab - 3.0 mg/kg; Type: EXPERIMENTAL; Interventions: Drug: Reslizumab | Intervention Type: DRUG; Name: Reslizumab; Assigned to Arm(s): Reslizumab - 0.3 mg/kg, Reslizumab - 3.0 mg/kg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: TARGIT: A Randomised Controlled Trial to Compare Targeted Intra-operative Radiotherapy With Conventional Post-operative Radiotherapy After Conservative Breast Surgery for Women With Early Stage Breast Cancer
Brief Summary: The purpose of this study is to evaluate whether a single fraction of radiotherapy given intra-operatively and targeted to the tissues at the highest risk of local recurrence is equivalent to standard post-operative external beam radiotherapy after breast conserving surgery in women with early stage breast cancer in terms of local relapse within the treated breast.


Options:
A: Arm Label: APBI; Type: EXPERIMENTAL; Interventions: Radiation: Accelerated partial breast irradiation | Arm Label: EBRT; Type: ACTIVE_COMPARATOR; Interventions: Radiation: External beam whole breast irradiation | Intervention Type: RADIATION; Name: Accelerated partial breast irradiation; Assigned to Arm(s): APBI | Intervention Type: RADIATION; Name: External beam whole breast irradiation; Assigned to Arm(s): EBRT
B: Arm Label: APBI utilizing 3D-CRT radiation; Type: EXPERIMENTAL; Interventions: Radiation: APBI utilizing 3D-CRT radiation | Arm Label: Whole breast irradiation; Type: OTHER; Interventions: Radiation: Whole breast irradiation | Intervention Type: RADIATION; Name: APBI utilizing 3D-CRT radiation; Assigned to Arm(s): APBI utilizing 3D-CRT radiation | Intervention Type: RADIATION; Name: Whole breast irradiation; Assigned to Arm(s): Whole breast irradiation
C: Arm Label: Group 1: WBI; Type: ACTIVE_COMPARATOR; Interventions: Radiation: whole breast irradiation | Arm Label: Group 2: PBI; Type: EXPERIMENTAL; Interventions: Radiation: 3-dimensional conformal accelerated partial breast irradiation, Radiation: brachytherapy, Radiation: MammoSite or other single-entry intracavitary device | Intervention Type: RADIATION; Name: 3-dimensional conformal accelerated partial breast irradiation; Assigned to Arm(s): Group 2: PBI | Intervention Type: RADIATION; Name: brachytherapy; Assigned to Arm(s): Group 2: PBI | Intervention Type: RADIATION; Name: whole breast irradiation; Assigned to Arm(s): Group 1: WBI | Intervention Type: RADIATION; Name: MammoSite or other single-entry intracavitary device; Assigned to Arm(s): Group 2: PBI
D: Arm Label: Intra-operative radiotherapy; Type: EXPERIMENTAL; Interventions: Device: Intrabeam | Arm Label: Post-operative radiotherapy; Type: ACTIVE_COMPARATOR; Interventions: Radiation: Post-operative radiotherapy | Intervention Type: DEVICE; Name: Intrabeam; Assigned to Arm(s): Intra-operative radiotherapy | Intervention Type: RADIATION; Name: Post-operative radiotherapy; Assigned to Arm(s): Post-operative radiotherapy

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: TARGIT: A Randomised Controlled Trial to Compare Targeted Intra-operative Radiotherapy With Conventional Post-operative Radiotherapy After Conservative Breast Surgery for Women With Early Stage Breast Cancer
Brief Summary: The purpose of this study is to evaluate whether a single fraction of radiotherapy given intra-operatively and targeted to the tissues at the highest risk of local recurrence is equivalent to standard post-operative external beam radiotherapy after breast conserving surgery in women with early stage breast cancer in terms of local relapse within the treated breast.


Options:
A: Arm Label: Whole breast irradiation (WBI); Type: ACTIVE_COMPARATOR; Interventions: Radiation: Whole breast irradiation (WBI) | Arm Label: Partial breast irradiation (APBI); Type: EXPERIMENTAL; Interventions: Radiation: Accelerated partial breast irradiation (APBI) | Intervention Type: RADIATION; Name: Accelerated partial breast irradiation (APBI); Assigned to Arm(s): Partial breast irradiation (APBI) | Intervention Type: RADIATION; Name: Whole breast irradiation (WBI); Assigned to Arm(s): Whole breast irradiation (WBI)
B: Arm Label: Standard or Hypofractionated radiotherapy; Type: ACTIVE_COMPARATOR; Interventions: Radiation: Whole Breast Irradiation + Boost or Hypofractionated irradiation | Arm Label: Accelerated Partial Breast Irradiation (APBI); Type: EXPERIMENTAL; Interventions: Radiation: Accelerated partial breast irradiation | Intervention Type: RADIATION; Name: Whole Breast Irradiation + Boost or Hypofractionated irradiation; Assigned to Arm(s): Standard or Hypofractionated radiotherapy | Intervention Type: RADIATION; Name: Accelerated partial breast irradiation; Assigned to Arm(s): Accelerated Partial Breast Irradiation (APBI)
C: Arm Label: Intra-operative radiotherapy; Type: EXPERIMENTAL; Interventions: Device: Intrabeam | Arm Label: Post-operative radiotherapy; Type: ACTIVE_COMPARATOR; Interventions: Radiation: Post-operative radiotherapy | Intervention Type: DEVICE; Name: Intrabeam; Assigned to Arm(s): Intra-operative radiotherapy | Intervention Type: RADIATION; Name: Post-operative radiotherapy; Assigned to Arm(s): Post-operative radiotherapy
D: Arm Label: APBI; Type: EXPERIMENTAL; Interventions: Radiation: Accelerated partial breast irradiation | Arm Label: EBRT; Type: ACTIVE_COMPARATOR; Interventions: Radiation: External beam whole breast irradiation | Intervention Type: RADIATION; Name: Accelerated partial breast irradiation; Assigned to Arm(s): APBI | Intervention Type: RADIATION; Name: External beam whole breast irradiation; Assigned to Arm(s): EBRT

Answer: C